| Written | 2008-12 | Nikolaos S Mastronikolis, Theodoros A Papadas, Panos D Goumas, Irene-Eva Triantaphyllidou, Dimitrios A Theocharis, Nikoletta Papageorgakopoulou, Demitrios H Vynios |
| Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece |
| Identity |
| ICD-Topo | C320-C323,C328-C329 LARYNX |
| Atlas_Id | 5087 |
| Phylum | Head and Neck: Larynx::Laryngeal tumor |
| Note | More than 95% of laryngeal tumours are squamous cell carcinomas (SCC). Most commonly, they arise from the glottic region of the larynx, namely the true vocal cords, so they usually present with changes in voice quality (i.e. hoarseness). The vast majority of patients have a history of smoking, while alcohol consumption is considered a significant co-factor. |
| Classification |
| Note | Light microscopy and occasionally immunohistochemistry are the main procedures of histological diagnosis and classification in laryngeal tumours. A histopathological classification of squamous cell carcinoma can be performed based on Broder's method. The use of microarray generated data is likely to radically improve disease sub-classification. True benign tumours constitute 5% or less of all laryngeal tumours. The most common benign tumour of the larynx is papilloma (85%). Other types include: chondroma, haemangioma, lymphangioma, schwannoma, neurofibroma, adenoma, granular cell myoblastoma, leiomyoma, rhabdomyoma, fibroma, lipoma and paraganglioma. |
 | |
| Note | Morphological appearance of laryngeal cancers after laryngectomy. |
| Laryngeal cancer mainly consist of conventional squamous cell carcinomas. Other laryngeal malignancies include:
Squamous cell carcinoma is further divided according to tumour location into four subtypes:
Glottic carcinomas represent the majority of laryngeal cancers (50%-60%), followed by the supraglottic carcinomas (30%-40%), while the subglottic carcinomas are uncommon (5% or less). |
| Clinics and Pathology |
| Etiology | The exact cause of laryngeal cancer is still unknown. However, several interrelated co-factors (mainly tobacco smoking and alcohol consumption), are clearly associated with an increased incidence in laryngeal cancer. Both of them increase the risk of cancer in a dose-dependent way. It appears that nicotine is not responsible for cancer itself, but polycyclic aromatic hydrocarbons and nitrosamines are carcinogenic. Poor diet and oral hygiene, vitamins deficiency, cirrhosis and depressed immune system often found in alcoholics may also contribute to cancerous process. Infections from herpes simplex and HPV, gastroesophageal reflex disease, anatomical malformations, Plummer-Vinson syndrome, steam and heat inhalation, thermal burns and exposure to ionizing radiation, asbestos, nickel, textile fibers and various chemicals, like formaldehyde, vinyl chloride and benzopyrenes, have also been considered as aetiological factors. Many ongoing studies are awaited to identify genetic factors and oncogenes that may be have an aetiological interest. |
| Epidemiology | The incidence of laryngeal carcinoma is relatively low in comparison to that of carcinomas of all organs. Laryngeal cancer comprises 2 to 5% of all malignant diseases diagnosed annually worldwide. The incidence is comparable to that of cancer of mouth and thyroid, but only one tenth as high as that of lung cancer. There are areas where the incidence is higher (greater than 10 per 10,000) including Spain, Italy, France, Brazil, India and the Afro-caribbean populations in parts of the USA. Low incidence areas (less than 2 per 100,000) include Japan, Norway and Sweden. Worldwide, the peak incidence of laryngeal cancer is highest in men aged between 55 to 65 years. The male-to-female ratio varies from 5 to 20:1, however the last decades there is a decrease in this ratio, because of an increase of laryngeal cancer in women. There is a notable social class difference, in that laryngeal cancer is twice as common in men with low socioeconomic status. It is also more common in people residing in cities than in rural areas. Most studies show that inhabitants of the most industrialized cities have an incidence of laryngeal cancer 2 to 3 times higher than that of rural inhabitants. These racial, social and urban variations may be reflect different lifestyle and habits and also confirm the already recognized harmful effects of tobacco and alcohol. Survival, in terms of the relative 5-year survival rate, for laryngeal cancer has been increasing the last four decades. However, long-term (10-year) relative survival rates have remained at about 50% for quite some time. |
| Clinics | The natural history and clinical picture of laryngeal cancer is dictated by its site of origin and its tendency to disseminate to the regional lymphatics. Progressive continuous hoarseness is the cardinal symptom of laryngeal carcinoma, especially the glottic one. Dyspnoea and stridor, pain, dysphagia, cough, swelling in the neck, haemoptysis, halitosis, reflective otalgia, tenderness of the larynx and weight loss can also occur during the course of disease. Neck metastases are more common in supraglottic cancers due to rich lymphatic network leading to early dissemination of primary tumour to the regional lymph nodes. On the contrary, glottic tumours because of the poor lymphatic network of the true vocal cords rarely present with regional neck metastases at the time of diagnosis. Staging of primary laryngeal tumours is dependent on the surface extent of the lesion to various sites within the same region of the larynx or from one region to the other or its extension beyond the larynx to adjacent organs as well as on the vocal cords mobility. Fixation of the vocal cords referred as T3 lesion independently of the initial tumour location and signifies a deeply invasive lesion. About 70% of the patients with supraglottic tumours at the time of diagnosis presented with advanced disease stage (III-IV). On the contrary, 75% of the glottic tumours presented with localized disease at initial stages (I-II). Distant metastasis is uncommon to be the first symptom of laryngeal cancer, however it can be found in about 5% at the time of initial presentation with appropriate investigation and lung comprises the most commonly involved site. At the time of diagnosis a second primary tumour can be found within the respiratory tract in 5% to 10% of the cases. Half of them are located in the lungs and have to be differentiated from distant metastases. In this setting it is important to perform a panendoscopy and appropriate radiological evaluation to exclude such pathology. |
| Pathology | Pathological diagnosis for laryngeal cancer is achieved after biopsy which is obtained at direct laryngoscopy under general anaesthesia. The vast majority of all laryngeal malignancies (95%) are conventional squamous cell carcinomas (SCC) and they vary according to their degree of differentiation to well, moderate and poor carcinomas. Glottic cancers are generally well differentiated and have a less aggressive behaviour in comparison with carcinomas at the other sites of the larynx. SCC often arises in a background of mucosal squamous dysplasia or carcinoma in situ and typically presents islands, tongues and clusters of atypical cells invading the laryngeal stroma. Features of squamous differentiation also comprise individual cell keratinisation, intercellular bridges and keratin pearls. Recognition of the less common variants like verrucous, spindle cell and basaloid SCC is significant because their biological course often is different from that of conventional SCC.
Except of conventional methods, various ancillary techniques provide information about a tumour that cannot be obtained by routine histopathologic examination. These methods have been applied to LSCC in order to evaluate a range of potential prognostic indicators, including DNA ploidy, proliferative activity, and oncogene amplification.
|
| Treatment | Over 95% of patients with LSCC are treatable. Causes of untreatability include the presence of distant metastases, very advanced locally and regionally tumours, poor general health, and patient's refusal. The standard options for treatment of LSCC are surgery, radiotherapy, chemotherapy or a combination of them. Radiotherapy is used in more than 70% of patients, surgery in about 55% and chemotherapy in about 10%. The management of laryngeal cancer varies in different parts of the world. However, it is widely accepted that early-stage LSCC can be adequately treated with single-modality therapy, either surgery or radiotherapy, with a 5-year local control of 85-95%. For more advanced disease (stages III and IV), a multimodality treatment based upon a combination of surgery and irradiation is the most common approach. Recently, new therapies based on a molecular basis of LSCC are in use or under development. The use of cellular tumour markers as therapeutic targets is being studied in order to block specific pathways involved in the cancerous process and tumour aggressiveness or invasiveness, restoring effective oncosuppression. Considering this, EGFR pathway is a good target for therapeutic interventions in LSCC. Several approaches can interfere with EGFR function and may be useful for anticancer treatment such as, the use of monoclonal antibodies (MAb) against the extracellular ligand binding domain, ligand-toxin conjugates that kill target cells following endocytosis, tyrosine kinase inhibitors that inhibit ligand-induced EGFR activation, and antisense oligonucleotides against EGFR mRNA. Furthermore, transient overexpression of the wild-type p53 gene could provide a potential molecular treatment strategy in LSCC. In head and neck cancer, the most used gene-delivery tool has been the recombinant adenovirus Ad-p53. A gene therapy approach using wild-type human p53 has already been demonstrated to induce apoptosis and radio-, chemosensitisation in cell lines. Thus, the use of p53 gene therapy in combination with radio- or chemotherapy could be considered a rational possibility. Another potential application is the treatment of dysplastic lesions, as p53 mutations seem to occur early in laryngeal carcinogenesis. However, the main problem of all these approaches, remains the absence of a really efficient, long-term gene-delivery system. |
| Prognosis | Once the diagnosis of laryngeal cancer has been documented the disease is staged according to the TNM classification system (stages I-IV) using the UICC/AJCC criteria. This system takes into account tumour size and location (T), lymph node involvement (N) and presence of distant metastasis (M). In general, the higher the stage (both overall and within each category) the poorer the prognosis. Small glottic cancers have better prognosis than supraglottic ones. The overall 5-year survival following treatment is 80% for glottic and 50% for supraglottic tumours, mainly because the latter present an increased incidence of nodal metastases. Nearly two-thirds of patients with supraglottic cancers have neck metastases at the time of initial treatment. Survival decreases by more than one third when clinically positive lymph nodes are present. Five-year disease free survival of patients with supraglottic cancer is 80% for stages I-II, 70% for stage III and 40% for stage IV. Patients with glottic cancers have a better long-term prognosis. Five-year disease free for stages I-II is 85%-90%, for stage III is 75% and for stage IV is 45%-50%. However, in cases with an extremely advanced local and regional disease the overall 5-year survival is less than 5%. |
| Cytogenetics |
| Note | Various chromosomal alterations have been observed in laryngeal SCC, such as 9p21 loss which contains the p16 gene, 11q13 which contains the CCND1 locus, 17p13 where the p53 gene is located, 3p with at least three putative tumour suppressor loci, 13q21, 6p and 8. Some of these alterations have been demonstrated to precede the development of cancer by several years, while others may be also detected as late late-occurring cytogenetic events. A few of them could be proposed targets for preventive strategies. Among the most frequent and relevant cellular changes in laryngeal carcinogenesis are those involving p53, cyclin D1 (CCND1), p16 and EGFR. The nuclear phosphoprotein p53 is involved in gene transcription, DNA synthesis and repair, cell cycle coordination and apoptosis. Disruption, or perturbation of p53 function have been detected not only in the laryngeal but almost in all head and neck cancers. p53 point mutations or deletions (also by LOH at 17p13) are frequent and p53 inactivation occurs in the transition from the preinvasive to the invasive state. Cyclin D1 is involved in cell cycle progression and interacts with cyclin-dependent kinases. When Cyclin D1 gene (CCND1) amplification is observed in precancerous and cancerous lesions, cyclin D1 is always overexpressed. In turn, cyclin D1 overexpression does not determine, but always anticipates gene amplification, which probably represents a more stable, non-reversible, alteration in tumour cells. Early in the cancerous process altered p53 gene function and CCND1 gene overexpression increase genetic instability and promote further genetic and chromosomal alterations, such as CCND1 amplification which is considered as the ultimate transforming event by the selection of a malignant subclone from a genetically altered field. |
| Genes involved and Proteins |
| Note | Environmental or genetic factors may be responsible for individual susceptibility to LSCC. A genetic predisposition for the development of LSCC is highly probable. Genetic polymorphisms of carcinogen-metabolizing enzymes have been found in tobacco smoke and there is evidence that they are associated with the risk of cancer development of the aerodigestive tract. Polymorphisms of genes encoding for arylamine N-acetyltransferases, human OGG1 DNA repair enzyme, CYP1A1, XRCC and glutathione S-transferases have been evaluated in relation to the risk LSCC development, however with controversial results. Identification of tumour suppressor genes and proto-oncogenes may be critical for an understanding of the biological initiation and progression of laryngeal cancer. Knowledge about the time course of a single molecular alteration may be helpful in its clinical use for molecular epidemiology, diagnostics or characterisation of laryngeal cancer. The perfect marker for molecular characterisation of LSCC should have the following properties: 1. not be constantly present in malignant cells, 2. associated with precise biological features and predictable clinical behaviour and, 3. easily detected by a standard, simple and reliable method on a small tissue sample. Unfortunately, no such marker yet exists. Alterations of p53 protein expression and mutations of the p53 gene have been proposed as independent predictors of recurrence in LSCC, however with controversial prognostic value. p53 protein overexpression has been detected in a high percentage of LSCC correlating well with p53 gene mutation. p53 gene mutation has been suggested more reliably than p53 protein overexpression for characterisation, predicting also the response to radiotherapy in LSCC patients. This observation is in accordance with the biological role of p53, which mediates apoptosis associated with DNA damage. Alterations in p53 status have been evaluated in healthy mucosa, precancerous lesions and tumour cells in order to predict the development of LSCC and secondary primary tumours. Mutations of p53 have also been evaluated to detect whether multiple primary tumours have a mono- or polyclonal origin, without however, definitive conclusions. In LSCC, degradation mediated by other cellular proteins, such as MDM2 or by human papillomavirus (HPV) E6 oncoprotein may represent alternative pathways leading to loss of p53 function. A p53 gene therapy approach has already been shown to induce apoptosis, radio- and chemosensitisation in cell lines and this, in combination with radiotherapy or chemotherapy, is a rational possibility. Another potential application considered the treatment of dysplastic lesions, as p53 mutations seem to occur early in laryngeal carcinogenesis. EGFR is frequently and early overexpressed in LSCC, mainly by post-translational mechanisms. EGFR expression retains a strong predictive value independently of treatment (surgery, chemotherapy and radiation) and adversely influences overall relapse-free and metastasis-free survival in LSCC. At present, EGFR is the most reliable biological marker for molecular characterisation, aggressiveness and invasiveness of LSCC. Telomerase activity often is present at high levels in most laryngeal cancer cells. It can at least partly depend on h-TERT gene (coding for catalytic subunit of telomerase) overexpression. It can be used for molecular epidemiology, diagnostics and targeting. An early CCND1 overexpression is often detectable without evidence of gene amplification; it can be used for molecular epidemiology but it seems to retain a lower prognostic value, if compared with CCND1 amplification. The latter is a marker of aggressiveness and has an impact on relapse-free and overall survival in LSCC. An overexpression of metalloproteases, hyaluronidases and cathepsin D is often detectable in tumour cells. These molecules are responsible for degradation of extracellular matrix and thus play an important role in tumour growth, invasion and metastasis, as well as in tumour-induced angiogenesis. In addition, overexpression of CD44 hyaluronan receptor in a less glycanated form is observed. Among the extracellular matrix components, the proteoglycan versican appeares to be overexpressed becoming the macromolecule characteristic of the tumour state and being another marker of aggressiveness. Similarly, hyaluronan is found in increased amounts and of rather smaller molecular size. Alterations, also, in the sulphation pattern of chondroitin/dermatan sulphate are observed, indicating different expression of sulphotransferases. Human papillomavirus (HPV) may affect epithelia with mucosal or epidermal tropism according to genotype. It has been reported that oncosuppressors such as p53 and pRb/RB1 are inhibited and degraded by HPV oncoproteins, while overexpression of oncogenes such as EGFR and cyclins A and B is induced. Type II oestrogen binding sites (EBS), normally found in laryngeal mucosa, have been reported that may partly mediate tumour growth inhibition by tamoxifen and quercetin and could be possible targets for chemoprevention and therapy. S100A2 has recently been described as an actual oncosuppressor with a prognostic significance stronger than simple histopathological grading. Its underexpression in cancer cells is inversely proportional to tumour differentiation. Methyl-phydroxyphenyllactate esterase (MEPHLase) low activity in LSCC is associated with poor differentiation and shorter overall survival and metastasis-free survival. Type 2 cyclo-oxygenase activity seems to promote tumour neoangiogenesis. However, evidence exists that low COX2 expression indicates poor differentiation and higher aggressiveness and invasiveness. Galectin-3 participates in a variety of cell processes and mediating cell-to-cell interactions. Its expression seems positively associated with tumour keratinisation and histological grade and a significant correlation was described between galectin-3 tumour positivity and longer metastasis-free and overall survival in LSCC patients. |
| Bibliography |
| Molecular markers in laryngeal squamous cell carcinoma: Towards an integrated clinicobiological approach. |
| Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M. |
| Eur J Cancer. 2005 Mar;41(5):683-93. Review |
| PMID 15763643 |
| Over-expression of p53 protein in human laryngeal carcinoma. |
| Anwar K, Nakakuki K, Imai H, Naiki H, Inuzuka M. |
| Int J Cancer. 1993 Apr 1;53(6):952-6. |
| PMID 8386140 |
| Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. |
| Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrandina G, Scambia G, Neri G. |
| Clin Cancer Res. 1996 Jan;2(1):175-80. |
| PMID 9816104 |
| Histopathology and pathologic prognostic indicators. |
| Cappellari JO. |
| Otolaryngol Clin North Am. 1997 Apr;30(2):251-68. Review |
| PMID 9052669 |
| Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. |
| Christopoulos TA, Papageorgakopoulou N, Ravazoula P, Mastronikolis NS, Papadas TA, Theocharis DA, Vynios DH. |
| Oncol Rep. 2007 Oct;18(4):855-60. |
| PMID 17786346 |
| Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. |
| Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A, Robinson RA. |
| Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13. |
| PMID 16946667 |
| Cancer statistics, 2004. |
| Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. |
| CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. |
| PMID 14974761 |
| The etiology and pathogenesis of laryngeal carcinoma. |
| Koufman JA, Burke AJ. |
| Otolaryngol Clin North Am. 1997 Feb;30(1):1-19. Review |
| PMID 8995133 |
| The molecular genetics of laryngeal cancer. |
| Loyo M, Pai SI. |
| Otolaryngol Clin North Am. 2008 Aug;41(4):657-72, v. Review |
| PMID 18570952 |
| Current opinion in diagnosis and treatment of laryngeal carcinoma. |
| Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. |
| Cancer Treat Rev. 2006 Nov;32(7):504-15. Epub 2006 Aug 22. Review |
| PMID 16920269 |
| The increased accumulation of structurally modified versican and decorin is related with the progression of laryngeal cancer. |
| Skandalis SS, Theocharis AD, Papageorgakopoulou N, Vynios DH, Theocharis DA. |
| Biochimie. 2006 Sep;88(9):1135-43. Epub 2006 Apr 25. |
| PMID 16690200 |
| UICC (International Union against Cancer): TNM classification of Malignant Tumours, 6th edition. |
| Sobin LH, Wittekind CH. (Eds) |
| Wiley-Liss, New York (pubs); 2002: 36-42. |
| Stage-related decorin and versican expression in human laryngeal cancer. |
| Stylianou M, Skandalis SS, Papadas TA, Mastronikolis NS, Theocharis DA, Papageorgakopoulou N, Vynios DH. |
| Anticancer Res. 2008 Jan-Feb;28(1A):245-51. |
| PMID 18383852 |
| Biochemical changes of extracellular proteoglycans in squamous cell laryngeal carcinoma. |
| Vynios DH, Theocharis DA, Papageorgakopoulou N, Papadas TA, Mastronikolis NS, Goumas PD, Stylianou M, Skandalis SS. |
| Connect Tissue Res. 2008;49(3):239-43. Review |
| PMID 18661351 |
| Tumours of the larynx, in Stell & Maran's Head and Neck Surgery, 4th edition. |
| Watkinson JC, Gaze MN, Wilson JA (Eds) |
| Butterworth-Heinemann, Oxford (pubs); 2000: 233-74. |
| Citation |
| This paper should be referenced as such : |
| Mastronikolis, NS ; Papadas, TA ; Goumas, PD ; Triantaphyllidou, IE ; Theocharis, DA ; Papageorgakopoulou, N ; Vynios, DH |
| Head, neck: Laryngeal tumors: an overview |
| Atlas Genet Cytogenet Oncol Haematol. 2009;13(11):888-893. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Tumors/LaryngealOverviewID5087.html |
| Other genes implicated (Data extracted from papers in the Atlas) [ 13 ] |
| Genes | ACVR1 | ADAM23 | CLIC1 | ECM1 | GRN | HLTF | INPP4B | KIF14 | LOXL4 | MIR106B |
| PDCD5 | RPA2 | SPAM1 |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Jun 30 11:24:57 CEST 2017 |
For comments and suggestions or contributions, please contact us